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In record time, microRNAs (miRNAs) have acquired the respected stature of important natural regulators of
global gene expression. Multiple studies have demonstrated that a large number of miRNAs are under the
control of various metabolic stimuli, including nutrients, hormones, and cytokines. Conversely, it is now
well recognized that miRNAs control metabolism, thereby generating a bidirectional functional link, which
perturbs energy homeostasis in case of disconnection in the miRNA-metabolism interplay. A challenging
road lies ahead for defining the role of miRNAs in the pathogenesis of diseases such as diabetes and for
establishing their usefulness as new medications and clinically reliable biomarkers.Introduction
Metabolism could be viewed as a box containing a gamut of
finely regulated biochemical processes that convert fuel from
food into the energy needed for organisms to develop, grow,
and survive. To maintain these complex biological destinies in
spite of internal and external perturbations, cells need to pro-
duce a constant supply of energy and derive the precursors
necessary for synthesis of nucleic acids, proteins, carbohy-
drates, and lipids. Cell homeostasis is maintained by the intricate
orchestration of a multitude of signaling pathways and ‘‘ener-
getic sensors’’ in tissues and organs. For maintaining this energy
balance, induction or repression of metabolic pathways must be
adapted to satisfy the energetic demands of cells. Themetabolic
pathways are governed by an integrative network of signaling
cascades, and conversely, the cell metabolic profile influences
signal transduction by incorporating various metabolic sensors
into the constellation of signaling molecules.
Anewclassof small noncodingRNAs, termedmicroRNAs (miR-
NAs), has added an additional level of complexity to the control of
metabolic homeostasis. miRNAs are short, single-stranded non-
coding gene products, typically 20–22 nucleotides long. The
mammaliangenomecodes for several hundredmiRNAs that regu-
late gene expression through modulation of target messenger
RNAs (mRNAs).miRNAbiogenesis consists of a series of sequen-
tial steps that convert primary miRNA transcripts into biologically
mature and active miRNAs (Bartel, 2009; Kim et al., 2009). Most
miRNAs interact with specific sequences in the 30 UTR of
mRNA. In contrast to plants, in which miRNAs are usually fully
complementary to theirmRNAtargetsandpromoteRNAcleavage
and degradation, metazoan miRNAs usually exhibit only partial
sequence complementarity to their mRNA targets and promote
translational repression rather than mRNA cleavage. However, a
recent publication reveals that in mammals, miRNAs would pre-
dominantly act to decrease target mRNA levels. Indeed, miRNA
destabilization of the mRNA target appears to be the chief cause
of reduced protein output (Guo et al., 2010). Computational pre-312 Cell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc.dictions of miRNA targets estimate that a single miRNA can regu-
late hundreds of differentmRNAs, suggesting that a large propor-
tion of the transcriptome is subjected tomiRNA regulation. Hence
miRNAsmaymodulate up to 30%of all human genes. The biolog-
ical importance ofmiRNAs is clearly evidencedby the diverse and
profound phenotypic sequels upon changes in their expression.
These alterations are associated with perturbed development
and pathological conditions. Indeed, miRNAs function as major
regulators of gene expression in many biological programs
including cell lineage differentiation, as well as embryonic and
organ development (Dumortier and Van Obberghen, 2012; Poy
et al., 2007). Furthermore, studies have demonstrated that a large
number of miRNAs are under the control of various important
signal-transduction cascades. These miRNAs contribute to the
regulation of different signaling pathways via the repression of
their target mRNAs, which results in the modulation of signal
transduction (Kim et al., 2009).
Although the complex mechanisms of action and the multi-
pronged impact of miRNAs on animal development, physiology,
and disease have not been fully elucidated, significant progress
has been made in deciphering the individual roles of certain
miRNAs in specific biological contexts. Furthermore, models of
the regulatory network of miRNAs have been proposed (Ebert
and Sharp, 2012; Leung and Sharp, 2010; Mendell and Olson,
2012). In this reviewwe summarize recent advances in our under-
standing of the emerging roles of miRNAs in the control of meta-
bolism in normal and pathological situations. The regulation of
miRNA expression by metabolic stimuli, including nutrients, hor-
mones, and cytokines, is addressed. Finally, we briefly discuss
extracellularmiRNAs and their potential use asbiomarkers of dis-
ease situations and the possibility of miRNA-targeted therapies.
Regulation of miRNA Expression by the Genomic
Environment
miRNAs are generated following intricate reactions that promote
the sequential cleavage, export, and loading of miRNA into
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each of these steps is a potential node of regulation and there-
fore provides expanding level of complexity to miRNA-depen-
dent gene modulation. The precise regulation of all these actors
in miRNA biogenesis was recently reviewed and will not be dis-
cussed here (Finnegan and Pasquinelli, 2013).
Transcription is one of the major regulatory steps in miRNA
biosynthesis. The features of miRNA gene promoters are similar
to the promoters of protein-coding genes, and miRNA transcrip-
tion is known to be controlled by transcription factors similar
to those of protein-coding genes (Kim et al., 2009). However,
depending on their genomic localization miRNAs can be under
the influence of their own promoter or of that of their host genes.
miRNA genes are categorized as intergenic, intronic, or exonic
according to their genomic location.
Intronic miRNAs are harvested in the introns of both protein-
coding and noncoding annotated genes. Approximately 40%
of mammalian miRNAs are located within the introns of pro-
tein-coding genes (Kim et al., 2009). These miRNAs can be pre-
sent as a singlemiRNA or as a cluster of several miRNAs. Intronic
miRNAs can be transcribed from the same promoter as their
host genes and processed from the introns of the host-gene
transcripts. This relationship sets the stage for a coordinated
expression pattern of intronic miRNAs and suggests that their
host genes could establish a concerted action between them.
One of the best-described examples of coregulation of mRNA
and miRNA is the association between miR-483 and IGF-2
(insulin-like growth factor-2), an insulin family member that plays
a crucial role in body-growth regulation. A few years ago, miR-
483 was identified as an intron-derived miRNA contained within
the second intron of the Igf-2 gene (Landgraf et al., 2007). More
recently, it was demonstrated that both miR-483 and Igf-2
mRNAs are generated from the same primary transcript. Further-
more, Igf-2-derived intronic miR-483 is involved in hepatic meta-
bolism through downregulation of its target Socs-3 (Ma et al.,
2011). Another remarkable example of coordination between
miRNA and host-gene action concerns the sterol-regulatory
element-binding protein (SREBP) transcription factors and their
intronic miRNAs mir-33a and miR-33b, which cooperate to
reduce cholesterol efflux and increase cholesterol biosynthesis
(Najafi-Shoushtari et al., 2010).
Most miRNAs are precisely regulated in a tissue- and develop-
ment-specific manner for the accomplishment of their special-
ized functions. As mentioned above, the expression pattern of
miRNAs depends in part on their host genes. However, inter-
genic miRNAs occur in the genomic regions distinct from the
known functional transcription units. Intergenic miRNAs can be
monocistronic or polycistronic and are known to have their
own promoters and other regulatory elements. For example,
pancreatic islet cell-specific expression of miR-375 is regulated,
at least partly, at the transcriptional level (Avnit-Sagi et al., 2009).
Indeed, a region in the miR-375 promoter, particularly sensitive
to mutation, contains consensus binding sequences for Hnf6
and Insm1, which have been implicated in the development
and function of pancreatic islets. Moreover, enhancer boxes
are required for full transcriptional activity, suggesting that the
miR-375 gene may be regulated by bHLH transcription factors
such as Ngn3 and NeuroD1 (Avnit-Sagi et al., 2009). In addition,
chromatin immunoprecipitation revealed that NeuroD1 interactswith conserved sequences both upstream and downstream of
the miR-375 gene.
Finally, exonic miRNAs, which occur less frequently than
intergenic or intronic miRNAs, are encoded by exons of non-pro-
tein-coding transcripts, and their transcription appears to be
controlled by their host-gene promoter (Rodriguez et al., 2004).
Regulation of miRNA Expression by the Metabolic
Environment
Cytokines
Maintainingmetabolic homeostasis requires a balanced immune
response, which is achieved by extracellular signals, including
cytokines. It is anticipated that perturbation of this equilibrium
could result in pathological situations. Indeed, increased levels
of markers and mediators of inflammation strongly correlate
with the occurrence of diabetes. miRNA expression is sensitive
to cytokines, and induction or repression of miRNAs in response
to inappropriate cytokine stimulation may lead to the disruption
of cellular homeostasis. For example, murine and human
pancreatic islets exposed in vitro to proinflammatory cytokines
display changes in their miRNA expression profiles (Roggli
et al., 2010, 2012). Among them, miR-21, miR-34a, miR-146a,
and miR-29 family members have been shown to contribute, at
least partially, to cytokine-mediated b cell dysfunction occurring
during the initial phases of type 1 diabetes (T1D) in nonobese
diabetic (NOD) mice. This indicates that proinflammatory cyto-
kines trigger a complex response resulting in modulation of
the expression of islet miRNAs, with important consequences
for b cell survival.
Hormones
One of the mechanisms controlling miRNA biogenesis includes
hormonal regulation. For instance, estrogens hamper miRNA
production by affecting a posttranscriptional event (Yamagata
et al., 2009). Specifically, estrogens suppress the levels of a
miRNA set including miR-125a and miR-145 in murine and hu-
man cells. In vitro, hormone-bound estrogen receptor a inhibits
miRNA maturation by associating with the Drosha complex
and preventing the conversion of pri-miRNAs into pre-miRNAs.
Furthermore, a role for miRNAs in the hormonally regulated
expression of estrogen target genes was revealed. Additional
studies have suggested that sex steroid hormones exert post-
transcriptional control through the regulation of miRNA process-
ing and expression (Cochrane et al., 2012; Klinge, 2009).
In some cases, miRNA modulation by hormones can re-
enforce the hormone-signaling pathway. For example, insulin,
a major hormone in the homeostasis of energy and metabolism,
was implicated in the regulation of miRNA expression. Indeed, in
human skeletal muscle, insulin decreases the expression of 39
miRNAs (Granjon et al., 2009). Their potential target mRNAs
code for proteins that appear to be mainly involved in insulin
signaling and ubiquitination-mediated proteolysis. Bioinformatic
analysis suggests that combinations of different downregulated
miRNAs act in concert to regulate gene expression in response
to insulin. In addition, impaired regulation of miRNAs by insulin
was found in skeletal muscle of type 2 diabetic (T2D) patients.
This suggests that in T2D some of these miRNAs might be
implicated in insulin resistance and/or be the consequence of it.
Further evidence for hormonal modulation of miRNA ex-
pression was provided by the demonstration in rodents thatCell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc. 313
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Figure 1. Conceptual Model of the Multipronged Impact of miRNAs
on Cell Metabolism
Metabolic stimuli (nutrients, hormones, and cytokines) induce changes in
miRNA expression and biogenesis that affect these stimuli, generating a
bidirectional functional relationship. Altered miRNA levels may cause changes
in gene expression through translational suppression or mRNA cleavage,
leading to cellular dysfunction favoring the occurrence of metabolic diseases.
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obesity is related to changes in the expression of several
miRNAs, which regulate b cell proliferation and survival (Jaco-
vetti et al., 2012). In isolated islets, activation of the G pro-
tein-coupled estrogen receptor GPR30 and the glucagon-like
peptide 1 receptor mimics the modulation in miRNA expres-
sion observed during gestation and obesity. Blockade of miR-
338-3p in b cells reproduces changes occurring during b cell
mass expansion and results in increased proliferation and sur-
vival both in vitro and in vivo. Thus, miR-338-3p is directly regu-
lated by estradiol and functions as an essential downstream
effector in the pathway.
Nutrients
In humans,miRNAs potentially modulate the expression of about
one third of mRNAs, and hence are anticipated to affect multi-
ple chief signaling pathways by targeting transcription factors,
secreted factors, receptors, and transporters. The plausible
importance of miRNAs in metabolism stems from the observa-
tion that misexpression of miRNAs occurs in several human
metabolic disorders. Given the key role of nutrients in the regu-
lation of metabolism, one could expect that changes in miRNA
expression in response to nutrient availability may affect, at least
partly, the regulation of cell metabolism. Although multiple
studies examined the dietary modulation of miRNA expression
in the context of nutrition and cancer prevention (Ross and
Davis, 2011), only scant information is available on dietary mod-
ulation of miRNAs in relation to metabolism. Nevertheless, evi-
dence is emerging that chief nutrients, such as glucose and
lipids, modify the expression of miRNAs in rodents and in
humans (Lovis et al., 2008b; Zampetaki et al., 2010). A common
method of identifying miRNAs potentially induced by nutrients
involves miRNome analyses of animals fed with particular diets.
This approach has revealed miRNAs with modified expression314 Cell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc.and led the way to their functional analyses. Thus, Carrer et al.
(2012) demonstrated that miR-378 and miR-378* (generated
from a common hairpin precursor) are upregulated in the liver
of mice fed a high-fat diet. Interestingly, genetic disruption
of miR-378 and miR-378* in mice confers resistance to high-
fat-diet-induced obesity. Furthermore, these transgenic mice
exhibit enhanced mitochondrial fatty acid metabolism and
elevated oxidative capacity in insulin target tissues (Carrer
et al., 2012). Taken together, miR-378 and miR-378* appear as
integral components of a regulatory circuit controlled by lipids
and impacting organismal energy homeostasis. Glucose was
also found to regulate miRNA expression. A few years ago our
group was the first to show that incubation of freshly isolated
rat pancreatic islets or INS-1E insulinoma cells with glucose
reduces miR-375 levels. In INS-1E cells, decreased miR-375
expression induced by high glucose concentration occurs
concomitantly with increased insulin signaling and with
augmented DNA synthesis. This could explain, at least in part,
the stimulatory action of glucose on b cell growth. At present,
the molecular route leading to this glucose effect on miRNA
expression is unknown (El Ouaamari et al., 2008; Keller et al.,
2012). Remarkably, our pioneering observation on glucose-
mediated miRNA expression is not unique to miR-375; similar
effects were recently observed for other miRNAs (Garcı´a-Segura
et al., 2013). In summary, a growing body of evidence suggests
that two major nutrients, glucose and lipids, take advantage
of the miRNA machinery to modulate energy metabolism. An
urgent challenge for metabolic disorders is to define the molec-
ular mechanisms linking nutrition and miRNA expression and
to discover derailment contributing to diseases such as obesity
and T2D.
miRNA-Induced Regulation of Metabolic Stimuli
Cytokines and Hormones
Although miRNA expression is regulated by different stimuli,
including cytokines and hormones, some miRNAs modulate
the secretion and action of these soluble mediators, generating
a bidirectional functional link (Figure 1). Actually, most, if not
all, molecular components of multiple signaling pathways may
be impacted by miRNAs according to computational algorithms
for miRNA-mRNA target predictions. However, despite a myriad
of theoretically possible interactions, only few have been exper-
imentally validated so far. For example, several miRNAs have
been implicated in the regulation of cytokine production and
action. Among them,miR-126 andmiR-193b affect the synthesis
of the adipocyte inflammatory chemokine CCL2 directly by
targeting the CCL2 mRNA and indirectly through a network of
transcription factors (Arner et al., 2012). Hence, these miRNAs
may be important regulators of adipose inflammation through
their effects on CCL2 release from human adipocytes and
macrophages.
Recent findings suggest that hormone-modulated miRNAs
play a substantial role in hormone-receptor-mediated gene
regulation, generating a feedback loop. Indeed, the expression
of some miRNAs modulated by sex-steroid hormones impacts
estrogen and progesterone action. Moreover, some miRNAs
appear to affect steroid hormone release, although themolecular
mechanisms remain to be revealed (Cochrane et al., 2012;
Klinge, 2012).
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Figure 2. Conceptual Views of miRNA Regulation of Insulin Secretion and Action
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ReviewLessons from Insulin Secretion and Action
We pay particular attention to miRNAs involved in the regulation
of insulin secretion and action, because insulin is the master
operator of glucose and lipid metabolism. Remarkably, miR-
375, which is the most abundant miRNA in pancreatic islets,
was the first miRNA to be implicated in hormone secretion
(Poy et al., 2004). Indeed, forced miR-375 expression in insuli-
noma cells leads to reduced glucose-stimulated insulin
secretion (GSIS) without interfering with glucose action on ATP
production and intracellular calcium levels. More specifically,
miR-375 directly interacts with the 30 UTR mRNA of myotrophin,
involved in insulin-granule fusion with the plasma membrane,
and thereby inhibits exocytosis. We found that miR-375 down-
regulates insulin-gene expression in INS1-E cells by acting
on phosphoinositide-dependent kinase-1 (El Ouaamari et al.,
2008), which was the second functionally identified miR-375
target. Interestingly, myotrophin is targeted by other miRNAs
such as miR-124 and let-7b (Krek et al., 2005), illustrating the
notion of convergent action by multiple miRNAs with the same
target (Figure 2A). Inversely, a single miRNA such as miR-124a
can target different mRNAs to regulate the same cellular process
(Figure 2B). Indeed, we reported that miR-124a binds to the 30
UTR mRNA of the forkhead box protein A2 (FoxA2) transcription
factor, which is a prime regulator of pancreatic development and
of genes involved in glucose metabolism and insulin secretion
(Baroukh et al., 2007). Increasing the miR-124a level in MIN6b cells decreases the Foxa2 protein, reducing its downstream
targets, including the ATP-sensitive potassium channel subunits
Kir6.2 and Sur-1, which are crucial for insulin release. In addition,
miR-124a alters the expression of other components of the insu-
lin exocytosis machinery (Lovis et al., 2008a). Indeed, miR-124a
increases the levels of SNAP25, Rab3A, and synapsin-1A and
decreases those of Rab27A and rabphilin-3A-like (Noc2). How-
ever, so far miR-124a has only been shown to directly interact
with the 30 UTR mRNA of Rab27A. miR-9 decreases insulin
secretion through its interaction with the mRNA of the Onecut-2
transcription factor, which reduces granuphilin/Slp4 expression
(Plaisance et al., 2006), and through Sirt1 (Ramachandran
et al., 2011).
The impact of miRNAs is not restricted to insulin secretion,
but also concerns insulin signaling and actions, which are medi-
ated by a complex, highly integrated network of pathways
(Taniguchi et al., 2006). Based on in silico analyses, the majority
of miRNAs appear to be able to modulate the protein abun-
dance of key signaling components of the insulin pathway by
acting at several levels. However, these interactions need to
be validated in the diverse insulin target tissues, which exert
specific functions in the organism. miRNAs are detected in
various metabolically active tissues including the endocrine
pancreas, liver, muscle, and adipose tissue. Some miRNAs
display a tissue-specific expression, suggesting a particular
function for these miRNAs. As mentioned earlier, miR-375 hasCell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc. 315
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whereas miR-122 is more specific to the liver, and they have
respective roles in b cell physiology and hepatic lipid meta-
bolism, as described below (Esau et al., 2006; Kru¨tzfeldt
et al., 2005). Inversely, some miRNAs are ubiquitously ex-
pressed and probably have a more general role in several
tissues, such as for let-7 (Figures 2 and 3). Indeed, the let-7
family regulates multiple aspects of glucose metabolism in the
pancreas, liver, and muscle (Frost and Olson, 2011). Further-
more, let-7 downregulates the phosphatidyl inositol-3-kinase
(PI3K) route at multiple sites by interacting with the 30 UTR
mRNA of insulin receptor (IR), insulin growth factor-1 receptor
(IGF-1R), and insulin receptor substrate-2 (IRS-2) (Zhu et al.,
2011) (Figure 2). Moreover, Lin28, a RNA-binding protein down-
regulating let-7, increases the protein abundance of IRS-2 in
C2C12 myoblasts and of IR and IGF-1R in skeletal muscle.
Although the effects of let-7 and Lin28 on the expression of
individual genes are modest, simultaneous regulation of multi-
ple components of signaling cascades could explain how this
RNA processing pathway coordinately regulates glucose meta-
bolism and insulin action (Zhu et al., 2011) (Figure 2B). Further-
more, miRNAs can modulate insulin signaling by acting on a
common target to mediate a convergent action (Figure 2A).
For instance, in addition to let-7, miR-33a and miR-33b (miR-
33a/b) interact with IRS-2, and miR-126 targets IRS-1 (Da´valos
et al., 2011; Ryu et al., 2011). Schematically speaking, multiple
miRNAs can have an additive action regulating different targets
(Figure 2C). Considering that Let-7, miR-33, and miR-29a down-
regulate IR, IRS, and PI3K, respectively, in hepatocytes and
liver, they could act in concert to decrease insulin action (Da´va-
los et al., 2011; Frost and Olson, 2011; Pandey et al., 2011; Zhu
et al., 2011). Finally, miRNAs regulating actors from the top of
the insulin cascade generate broad effects, as is the case for316 Cell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc.let-7, whereas miRNAs acting on down-
stream molecules are likely to exert
more specific effects, as seen with
miR-29 (Figure 2B). Indeed, miR-29a/c
overexpression in primary hepatocytes
and livers from mice decreased the
protein levels of peroxisome prolifer-
ator-activated receptor g coactivator-1a
(PGC-1a) and glucose-6-phosphatase
(G6Pase), thereby reducing glucose
production. Conversely, loss of miR-
29a/c function in primary hepatocytes
augments the protein levels of PGC-1a
and G6Pase and increases glucose
production. Interestingly, forced PGC-
1a expression increases miR-29a/c
expression in primary hepatocytes, thus
forming a negative feedback regulation
loop (Liang et al., 2013). At the organ-ismal level, miR-29a/c lower fasting glycemia levels by blocking
hepatic gluconeogenesis through the regulation of downstream
actors of the insulin cascade.
miRNA-Induced Regulation of Energy Metabolism
By regulating the expression of important components of
signaling pathways, miRNAs participate in a wide spectrum of
biological processes (Figure 1). Because of this, they govern
key aspects of organismal homeostasis, and their aberrant
expression eventuates in disease situations. A general con-
sensus exists on the role of miRNAs as fine-tuners of metabolic
processes in mammals (Rottiers and Na¨a¨r, 2012). Glucose and
lipid homeostasis requires the presence of both insulin and the
responsive target tissues to generate the appropriate biological
program.
Glucose Metabolism
Glucose homeostasis is mainly regulated by the antagonistic
couple formed by insulin and glucagon, secreted by pancreatic
b and a cells, respectively. miRNAs involved in secretion and/
or action of these hormones are destined to impact glucose
metabolism. Although several miRNAs described above directly
interact with components of the insulin secretion machinery, to
the best of our knowledge, none have been directly implicated
in glucagon secretion. Obviously, miRNAs critical for the devel-
opment of the endocrine pancreas and the establishment of
the appropriate islet cell mass will potentially exert an indirect
effect on hormone secretion and glucose homeostasis (Dumort-
ier and Van Obberghen, 2012). Interestingly, miR-375 knockout
mice suffer from hyperglycemia and glucose intolerance associ-
ated with increased gluconeogenesis (Poy et al., 2009). This
hyperglycemia is thought to be primarily caused by hypergluca-
gonemia resulting from disrupted islet architecture with an in-
crease in a cell number in the islet core rather than increased
Cell Metabolism
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only the a but also the b cell mass by modulating a group of
genes governing cell growth and proliferation. To sum up,
studies in cultured cells and in animals indicate that miR-375
exerts multiple and distinct effects and participates not only in
pancreas development by regulating b and a cell mass, but
also in the safeguard of b cell physiology.
Additional miRNAs have been implicated in glucose meta-
bolism and metabolic homeostasis in intact animals (Figure 3).
The Lin28/let-7 axis regulates glucose metabolism, partially by
targeting key insulin signaling components as mentioned above
(Zhu et al., 2011). Indeed, muscle-specific Lin28a loss or let-7
overexpression induces insulin resistance and impaired glucose
tolerance inmice.Moreover, global and pancreas-specific trans-
genic mice overexpressing let-7 display impaired glucose toler-
ance and GSIS (Frost and Olson, 2011). Reduced miR-103/107
expression in mice leads to improved insulin action and glucose
homeostasis, whereas forced miR-103/107 expression is
sufficient to induce impaired glucose homeostasis coupled to
increased gluconeogenesis (Trajkovski et al., 2011). Improve-
ment in insulin action by these miRNAs is attributed in part to
caveolin-1 inhibition, which influences IR stabilization in lipid
rafts. Mice deficient in the miR-143/145 cluster are protected
from insulin resistance following a high-fat diet, whereas trans-
genic mice with induced hepatic overexpression of miR-143,
but not miR-145, suffer from diminished insulin-stimulated Akt
activation and glucosemetabolism (Jordan et al., 2011). Interest-
ingly, the oxysterol-binding-protein-related protein 8 (ORP8), a
regulator of insulin-induced Akt phosphorylation in the liver,
was identified as a miR-143 target by quantitative mass spec-
trometry. Recently, miR-802 was shown to inhibit Hnf1b in the
liver, leading to decreased insulin action and impaired glucose
tolerance in mice (Kornfeld et al., 2013). A fascinating and unex-
pected role of the cardiac-specific miR-208 in metabolism was
recently revealed (Grueter et al., 2012). Indeed, reduced miR-
208 expression protects mice from obesity and reduces
whole-body insulin action and glucose tolerance. These remark-
able data uncover a novel role of the heart in systemic energy
homeostasis.
A hallmark of the models discussed in this paragraph is that
the misexpression of a single miRNA in one or more insulin-sen-
sitive tissue(s) suffices to perturb whole-body glucose homeo-
stasis, indicating that these miRNAs affect major metabolic
pathways (Figure 3).
Lipid Metabolism
Although the liver-specific miR-122 and miR-33a/b are recog-
nized to directly regulate lipid metabolism, a number of other
miRNAs are also implicated (Rottiers and Na¨a¨r, 2012). miR-122
was the first miRNA identified as tissue specific and is the
most abundant miRNA in the liver. Among several studies, two
pioneered in revealing the role of miR-122 in lipid metabolism
regulation by in vivo antisense targeting (Esau et al., 2006; Kru¨tz-
feldt et al., 2005). Indeed, miR-122 inhibition leads to decreased
plasma cholesterol and triglyceride levels associated with
altered cholesterol biosynthesis and increased fatty acid oxida-
tion. Although several genes are regulated by miR-122, most of
them have not been validated as direct targets. Several groups
have highlighted the regulation of lipid homeostasis by the
bifunctional SREBF2-miR-33a locus (Rottiers and Na¨a¨r, 2012).Indeed, the Srebf2 gene encodes both SREBP2, which modu-
lates cholesterogenic gene expression, and miR-33a located
within an intronic region of the gene. miR-33b is found in an
intronic region of the Srebf1 gene encoding SREBP1a/c, which
modulates lipogenic gene expression. Interestingly, miR-33a
and miR-33b target components of fatty acid degradation and
cholesterol efflux. Therefore, SREBP proteins and miR-33 act
in concert with their host genes as crucial regulators of choles-
terol and lipid homeostasis.
Other miRNAs have been related to lipid metabolism such as
miR-370, reported to control the expression of miR-122 and its
targets (Iliopoulos et al., 2010). miR-758 is thought to posttran-
scriptionally modulate the levels of the ABCA1 cholesterol trans-
porter and cholesterol efflux from macrophages (Ramirez et al.,
2011). Although the liver is the main tissue for lipid metabolism,
adipose tissue likewise plays a crucial role, notably in lipid
storage. Numerous miRNAs are involved in white-adipocyte
differentiation including miR-103/107, miR-378/378*, miR-143,
miR-21, miR-27a, and miR-130 (Hulsmans et al., 2011). In
addition, miR-133 was recently shown to participate in brown-
adipocyte differentiation (Trajkovski et al., 2012).
Amino Acid Metabolism
Amino acid metabolism is also modulated by miRNAs. For
instance, in mammals, miR-29b exerts control on a metabolic
pathway of amino acid catabolism. Thus, miR-29b targets the
mRNA of the dihydrolipoamide branched chain acyltransferase
component of branched-chain keto acid dehydrogenase, which
catalyzes the first irreversible step in branched-chain amino acid
(BCAA) breakdown (Mersey et al., 2005). Increased miR-29b
expression downregulates the rate-limiting step of BCAA degra-
dation with accumulation of BCAA. BCAA homeostasis is crucial
given that these amino acids account for up to 20% of the amino
acids found in most proteins. Moreover, BCAAs play important
roles in the regulation of hormone secretion (e.g., insulin), protein
synthesis, and autophagy, notably through the modulation of the
mammalian target of rapamycin pathway.
miRNAs Mediating a Stress Response
Biological systems are characterized by resistance to environ-
mental changes to ensure proper health, but failure in the pro-
tective mechanisms will set the stage for exacerbated disease
risk (Li et al., 2009). A groundbreaking concept in this context
is that miRNAs are instrumental in generating biological robust-
ness. Indeed, it is possible that miRNAs buffer fluctuations in
gene expression generated by perturbations inside and/or
outside organisms. A trailblazing example showed that in
Drosophila, miR-7 is necessary for the proper photoreceptor
development in eyes under conditions of temperature fluctuation
(Li et al., 2009). Even though biological vigor is usually associated
with phenotypic stability, physiological responses to stress such
as aging, inflammation, or perturbed nutrient availability also
need to be reproducible and robust (Mendell and Olson, 2012).
Inappropriate responses often lead to pathological situations
such as accelerated aging and diabetes.
Aging and Longevity
Aging is a complex, naturally occurring process characterized by
an evolving homeostatic imbalance due to inapt metabolism, a
progressive impairment of the organism to cope with environ-
mental stress, and a growing frailty with increasing risk ofCell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc. 317
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act as aging modulators was gathered inC. elegans (Boehm and
Slack, 2005). Studies in mammals suggest that miRNAs have
similar roles in this overarching biological phenomenon. Indeed,
comparison of miRNA profiles in younger and older mammals
reveal that several miRNAs are differentially expressed (Smith-
Vikos and Slack, 2012). These miRNA patterns generally appear
to be tissue-specific, which is consistent with the tissue-specific
functions of aging signaling pathways. For example, in mice the
level of the key miRNA regulatory protein Dicer drops with age
in adipose depots together with a declining level of several
miRNAs. A similar decrease in Dicer with age occurs in
C. elegans and in preadipocytes from elderly humans (Mori
et al., 2012). In C. elegans and mice, this reduced Dicer level is
prevented by caloric restriction, themost efficacious intervention
delaying senescence and the onset of age-associated diseases.
Dicer knockdown in cells with resulting decrease in multiple
miRNAs impairs the ability of preadipocytes to respond to stress.
Moreover the adipose-tissue-specific Dicer knockout mouse is
more sensitive to oxidative stress. Thus, miRNA processing in
adipose-related tissues plays an important role in aging, stress
survival, and longevity (Mori et al., 2012). By contrast, when
miRNA expression in the skeletal muscle of young humans
was compared with that of older ones, 18 miRNAs were found
to be differentially expressed, and let-7b and let-7ewere upregu-
lated (Drummond et al., 2011). These let-7 family members
repress the cell-cycle regulators CDK6, CDC25A, and CDC34,
as well as PAX7, which is important for muscle satellite cell
turnover.
Significant progress has been made in delineating biochem-
ical and molecular pathways involved in aging. Twenty years
ago it was discovered that the insulin/IGF-1 signaling (IIS)
pathway influences lifespan (Kenyon et al., 1993). IIS is an evolu-
tionarily conserved cascade that modulates longevity across
many species. Multiple miRNAs participating in the regulation
of this pathway have been identified. Among them is the miR-
17-92 cluster, which, along with its paralogous clusters, miR-
106a-363 and miR-106b-25, decreases with age and regulates
cellular senescence (Grillari et al., 2010). These miRNAs target
PTEN (phosphatase and tensin homolog), a lipid phosphatase
inhibiting PI3K action. It is thought that their repression during
aging causes an increase in PTEN levels, which results in atten-
uation of the IIS pathway. Other miRNAs target components of
the IIS pathway. For example, in mouse brain and human fibro-
blasts, miR-470, miR-669b, and miR-681 suppress expression
of the IGF1-R, which results in decreased phosphorylation of
Akt and FOXO3. The latter is an important checkpoint of meta-
bolic regulation, associated with human longevity (Pawlikowska
et al., 2009). Although numerous miRNAs are differentially ex-
pressed during mammalian aging, many fundamental questions
regarding their precise role and impact remain. Furthermore, for
a grasp of the true influence of miRNAs in the multidimensional
process of aging, it is crucial to identify the upstream factors
that control the differential expression of these molecules during
senescence at the cell, tissue, and organism levels.
Inflammation
It is widely recognized that chronic low-grade inflammation plays
a key role in the initiation, propagation, and development of318 Cell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc.metabolic disorders including T2D. Indeed, excessive levels of
nutrients, including glucose and lipids, stress the pancreatic
islets and insulin-sensitive tissues, leading to the local produc-
tion and release of cytokines, which promotes inflammation
(Donath and Shoelson, 2011). As mentioned above, miRNA
expression is sensitive to nutrients and cytokines, and con-
versely, some miRNAs modulate the secretion and action of
cytokines, generating a bidirectional functional link. Indeed,
several miRNAs are implicated in the inflammatory process,
acting as positive or negative regulators (Hulsmans et al.,
2011). During obesity, macrophages progressively infiltrate into
the adipose tissue, where they produce inflammatory chemo-
kines, contributing to chronic low-grade inflammation (Donath
and Shoelson, 2011). This increased infiltration is a key event
in obesity, insulin resistance, and atherogenesis. It has been pro-
posed that miRNAs could be common regulators of these path-
ogenic processes in adipose and vascular tissues (Hulsmans
et al., 2011). According to this view, a common set of miRNAs
including let-7, miR-21, miR-34a, andmiR-143 appear to display
the same functions in the two tissues. However, further progress
in functional analysis and the discovery of synergetic actions is
required for uncovering causal connections to inflammation.
Notwithstanding this, recent studies point to a link between
specific miRNAs, inflammation, and T2D. For example, in Asian
Indian T2D patients the miR-146a levels in peripheral blood
mononuclear cells negatively correlate with insulin resistance,
poor glycemic control, and circulating tumor necrosis factor a
and interleukin-6 levels (Balasubramanyam et al., 2011). Like-
wise, miR-146a appears to control the induction of NF-kB-
responsive genes. Indeed, in T cells, miR-146a is an important
member of the negative feedback loop controlling the induction
of NF-kB-responsive genes involved in various aspects of T cell
activation (Yang et al., 2012). Another member of the miR-146
family, miR-146b-5p, exerts anti-inflammatory actions during
obesity (Hulsmans et al., 2012). Finally, a possible role of miR-
107, a Toll-like-receptor-regulated miRNA, in modulating the
inflammatory process that might lead to T2D has been pro-
posed. Hence, it was suggested that miR-107 may be the link
between obesity, inflammation, and insulin resistance (Foley
and O’Neill, 2012).
Autophagy
Autophagy corresponds to autodigestion of cell components
and recycling of biological building elements destined for reuse.
Autophagic vacuole formation and delivery is an evolutionarily
conserved catabolic pathway in which complex cell building
blocks are engulfed within vesicles and degraded into small mol-
ecules for providing nutritional elements to be utilized again
(Kroemer et al., 2010). This critical process allows cells to gain
survival advantages under various stress situations due to
growth and environmental changes. Recently, Kovaleva et al.
(2012) revealed that autophagic flux can be regulated by Dicer.
On the flip side, autophagy engages regulation of Dicer and
Ago proteins, pointing to a fundamental connection between
miRNAs and autophagic flux (Gibbings et al., 2012).
In mammals, autophagy induction is initiated by the ULK com-
plex, composed of ULK1, ULK2, ATG13, FIP200, and ATG101
(Kroemer et al., 2010). miRNAs interfere at the most upstream
event in autophagosome formation. For instance, miR-20a and
miR-106b bind to the ULK1 mRNA and reduce its protein level
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vesicle-nucleation step, which is initiated by the beclin-1/class III
PI3K complex. Among the members of this complex, beclin-1 is
a potential target of numerous miRNAs. For example, miR-30a,
miR-376b, and miR-519a bind directly to beclin-1 30 UTR
mRNA (Zhai et al., 2013). Interestingly, Beclin-1 lies at the cross-
road between autophagy and apoptosis (Kang et al., 2011), sug-
gesting that, depending on the stress response, miRNAs could
cross-regulate autophagy and apoptosis.
The elongation and enclosure of membranes thought to be
critical for autophagosome formation is associated with ubiquiti-
nation-like conjugations. Several miRNAs have been identified
as regulators of this step. ATG7, required for the initial step in
conjugation systems, was recognized as a target of miR-375
(Chang et al., 2012). miR-30a, besides its association with the
beclin-1 complex, was implicated in the ATG12-ATG5-ATG16
complex. Other potential regulators of ATG5-ATG12 conjugation
include miR-101, miR-181a, miR-374a, and miR-630 (Zhai et al.,
2013).
The lysosomes are the final destination for autophagosomes,
thereby forming the autolysosome, in which cargo is exposed
to lysosomal hydrolases that lead to its breakdown. Finally, the
resulting macromolecules are transported back into the cytosol
through membrane permeases for reuse. Intriguingly, to the
best of our knowledge, no miRNAs directly affecting the fusion
process have been revealed so far.
miRNAs in Diabetes
Diabetes itself represents a state of cellular stress induced
by hyperglycemia and/or hyperlipidemia. Indeed, diabetes is
defined as chronic hyperglycemia due to pancreatic failure in
T1D and to a combination of insulin resistance and insufficient
insulin secretion in T2D. Given the general role of miRNAs on
cells and organisms, the tantalizing hypothesis that their misex-
pression could be associated with disease situations, including
metabolic disorders such as diabetes, emerged very early on.
In the previous sections we discussed the impact of a series of
miRNAs on insulin secretion and action, which reflects a direct
or indirect causal relationship depending on the targets. Here,
we briefly review the miRNAs found to be misexpressed in
diabetes. It must be stressed that these miRNA alterations
could participate in the disease process and/or be the conse-
quence of it.
miRNA Misexpression in Diabetes
To assess the involvement of miRNAs in diabetes, most research
efforts address their expression profile in animal models and,
when possible, in diabetic patients.
Concerning T1D, NOD mice correspond to a well-character-
ized spontaneous model closely resembling the human disease.
Among several miRNAs differentially expressed in islets from
NOD mice, miR-21, miR-34a, and miR-29a/b/c are upregulated
(Roggli et al., 2010, 2012). Interestingly, these miRNAs were
reported to inhibit different targets involved in b cell death,
including the tumor suppressor programmed cell death protein
4 (PDCD4) and the antiapoptotic proteins Mcl1 and Bcl2 (Guay
et al., 2012) (Figure 2C).
Because T2D is a multicausal and heterogeneous disease,
animal models fail to regroup all pathological hallmarks observed
in humans. However, the db/db mice deficient in leptin receptorfulfill minimal criteria justifying their use in miRNA studies. Among
several miRNAs described to be altered in this model, miR-34a
and miR-146 are upregulated in islets (Lovis et al., 2008b), and
miR-29 family members and miR-125a are increased in other
insulin target tissues (He et al., 2007; Herrera et al., 2009). Given
that T2D is often associated with obesity, several studies were
performed in ob/ob mice deficient for leptin or in diet-induced
obesity (DIO) mice. For instance, miR-103 and miR-107 expres-
sion is altered in the liver and white adipose tissue of ob/ob and
DIO mice (Trajkovski et al., 2011). miR-143 and miR-802 are
increased in the liver of db/db and DIO mice (Jordan et al., 2011;
Kornfeld et al., 2013). To sum up, the expression of a number of
miRNAs is dysregulated in diabetic and obese animal models.
Concerning human studies, a meager number of reports have
appeared because of limitations inherent to tissue accessibility.
Gallagher et al. (2010) performed a genome-wide analysis of
mRNAs and miRNAs on skeletal muscle from subjects without
or with T2D. A list of differentially expressed miRNAs was iden-
tified, and several of them are predicted to target molecules
relevant to metabolic disease. Additionally, Klo¨ting et al. (2009)
compared miRNA expression in omental and subcutaneous
adipose tissue of individuals with normal glucose tolerance or
newly diagnosed T2D. A significant correlation was found
between the expression of several miRNAs and both adipose-
tissue morphology and key metabolic parameters. More
recently, investigation of a specific miRNA set in human islets
from nondiabetic and diabetic subjects revealed that miR-21 is
significantly increased, whereas miR-375 merely shows a
tendency (Bolmeson et al., 2011). This contrasts with another
study on the correlation between miR-375 expression and islet
amyloid deposition reporting that miR-375 is upregulated in
islets of T2D (Zhao et al., 2010).
To summarize, although changes in miRNA expression in
human diabetes exist, the limited available data do not draw a
clear picture. Important pitfalls possibly exist due to the small
cohort size, the lack of uniformity in miRNA measurement tech-
niques, and confounding factors related to age, body mass
index, and sex differences (Becker and Lockwood, 2013).
Extracellular miRNAs as Biomarkers of Diabetes
Although a consensus exists on the importance of miRNAs in the
cells wherein they are produced (i.e., in situ effects), the demon-
stration that miRNAs circulate in blood points to ex situ actions.
The possibility of miRNAs acting at a distance opens an entirely
novel repertoire of biological functions. miRNAs found in blood
could originate in organs or tissues and/or be passively released
from broken cells following injury, apoptosis, or necrosis (Zer-
necke et al., 2009). Independently of these two possible scripts,
the exported versus passively released miRNAs found in blood
could exert a paracrine function by acting on neighboring cells
and even extend their action at a distance. For both actions
(i.e., paracrine and remote), a certain stability of these molecules
is a prerequisite. Indeed, circulating miRNAs appear to be
remarkably robust despite the austere conditions to which they
are subjected. This is compatible with the fact that circulating
miRNAs travel as passengers of several transportation vehicles
that offer protection from ribonuclease activity. Although the
secretorymechanism ofmiRNAs remains obscure, different sce-
narios have been proposed for their carriage. According to one,
circulating miRNAs are part of microvesicles or exosomes orCell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc. 319
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nificant portion of circulating miRNAs in plasma are associated
with the RNA-binding proteins Ago2 and NPM1 (Turchinovich
et al., 2011).
An important spin-off provided by the fact that miRNAs are
found in biological fluids points to their potential use as bio-
markers for disease states and to the possible development of
miRNA-based therapeutics. Several groups have revealed an
altered profile of circulating miRNAs in various metabolic dis-
eases such as T2D. For example, a plasma miRNA signature
for T2D was identified in a cohort of 80 patients (Zampetaki
et al., 2010). Among the 12 miRNAs correlated with the disease,
miR-126 shows a gradual decrease from normal to impaired
glucose tolerance. Previously, miR-126 was found to be highly
enriched in endothelial cells for governing the maintenance of
vascular integrity, angiogenesis, and vessel repair (Fish et al.,
2008; Wang et al., 2008). T2D is one of the major risk factors of
cardiovascular disease and is associated to endothelial dysfunc-
tion with micro- and macrovascular complications. Generally
speaking, cardiovascular diseases cause most of the increased
morbidity and mortality of diabetic patients. Although additional
validation in large cohorts is needed, loss of endothelial miR-126
in plasma might reflect altered endothelial function, and thus
could have a prognostic value for the development of diabetic
vascular complications.
More recently, Kong et al. (2011) focused on the increased
expression of seven diabetes-related circulating miRNAs
(miR-9, miR-29a, miR-30d, miR-34a, miR-124a, miR-146a, and
miR-375) during the pathogenesis of the disease. Their upregu-
lated expression dovetails with their previously described
involvement in the pathogenesis of the disease, in that all of
these miRNAs were identified as negative regulators of the
expression, production, secretion, or action of insulin (Guay
et al., 2012). As mentioned above, in human and mouse pancre-
atic islets miR-375 displays the most robust expression, and b
cells could thus be viewed as a major supplier of blood-borne
miR-375. Consequently, the measurement of miR-375 plasma
levels could represent an attractive means for estimating b cell
mass in insulin-resistant patients before the development of
pancreatic failure in order to adapt the treatment.
In summary, the discovery that miRNAs are present in a stable
form in several body fluids, including blood, suggests that extra-
cellular miRNAs hold promise to serve as novel biomarkers for
metabolic disorders and/or their associated complications.
The latter aspectwouldbeespecially useful for diabetes, forwhich
prognostic markers for complications are missing. The validated
use of miRNAs as bona fide disease biomarkers is a ways off, as
several key issues need to be addressed, including the following
ones: On the technical side, the lack of standardization of the
methods for measuring miRNA levels generates limitations for
the validation and verification of the profiles obtained by different
laboratories and platforms. In addition, the use of miRNAs as
biomarkersnecessitates theuniformity ofpreclinical sampleprep-
aration, which is too often neglected. Furthermore, at present it
remains to be sorted out whether extracellular miRNAs, and
particularly the circulating ones, merely reflect the disease and/
or are actively participating in the disease process. Finally, given
the pleiotropic actions of most miRNAs, some of which have
opposing actions, it must be determined whether aberrant320 Cell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc.expression of miRNAs per se should be used as biomarker, or
whether a chart of misexpressed miRNAs affecting a particular
disease-related biological process would be more informative.
miRNAs as Therapeutic Tools
The central implication of miRNAs in metabolism and associated
disorders combined with the remarkable stability of extracellular
miRNAs raises the question of the possibility of miRNA-targeted
therapies. miRNA mimics or miRNA inhibitors can be used to
elevate or block the activity of miRNAs that drive disease initia-
tion and/or progression. The ability to therapeutically manipulate
miRNA expression and the pharmacokinetic and dynamic prop-
erties of current mimic and antimiR designs were recently
reviewed (Quiat and Olson, 2013) and will be not discussed here.
In a groundbreaking publication, Janssen et al. (2013) showed
for the first time in humans the ability to therapeutically manipu-
late miRNA expression and function. Using LNA-miR-122
(Miravirsen) in patients with chronic hepatitis C virus (HCV) infec-
tion, they observed prolonged dose-dependent reductions in
HCV RNA levels without evidence of viral resistance. This work
provides promising expectations that antimiRs could become
new medications; however, additional clarification is eagerly
awaited, as the exact mechanism by which Miravirsen reduces
HCV replication remains elusive. Indeed, the Miravirsen effect
is thought to be based on 50 UTR binding of miR-122 and not
on a ‘‘classical’’ 30 UTR binding of a predicted target gene.
Another key challenge to be resolved concerns the delivery
strategy. Evidently, targeting the liver or pancreas demands
different requirements than reaching readily accessible sites
such as skin and bones. Some strategies are based on systemic
approaches including the use of antibody-based delivery
agents, nanoparticles, and liposomes to target and/or restore
miRNAs in specific cell types (Langer et al., 2012). Interestingly,
a recent study demonstrates that miRNAs present in food
appear to regulate the expression of target genes in mammals
(Zhang et al., 2012). These intriguing results raise questions
about food-derived miRNAs and their active role in human
health, but they also open unexpected perspectives as an oral
delivery strategy. However, to prove the salutary effects of this
promising approach, several issues must be solved, including
the desired delivery specificity, the possible immune stimulation,
and the toxic accumulation in tissues. One of the most attractive
strategies of restoring miRNAs in disease is through adeno-
associated viruses (AAVs). The availability for numerous different
AAV serotypes allows for potential tissue enrichment as a result
of the natural tropism of AAV subtypes. For example, administra-
tion of AAV6, AAV8, and AAV9 appears to be efficient for genetic
manipulation of the pancreas in vivo (Jimenez et al., 2011). How-
ever, some tissues remain refractory to transduction with the
available serotypes (Daya and Berns, 2008). In addition, the
host immune response remains a concern. Thus, although very
promising studies are emerging in the field of miRNAs as thera-
peutic tools, the whole area is in its infancy, andmore knowledge
is needed on current obstacles ranging from adequate delivery
strategies to possible side effects.
Conclusions and Future Directions
More than a thousand miRNAs have been identified in rodents
and humans; however, only the tip of the iceberg is visible with
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their biological actions suggests that miRNAs are at the core of
mechanisms involved in metabolism regulation. Remarkably,
the relationship between miRNAs and metabolism appears as
a bidirectional link. Indeed, miRNAs impinge on metabolism by
interacting with the production and/or signaling of key players
involved in metabolic regulation. By the same token, miRNA
expression and processing are modulated by major metabolic
stimuli such as glucose and hormones. This mutually enriching
relationship between miRNAs and metabolism is likely to partic-
ipate in the complex regulation of homeostasis. Hence, discon-
nection of this bidirectional interworking is destined to contribute
to disease situations. Although the elementary vocabulary of the
miRNA language has been decoded, many urgent questions
remain to be addressed.
A central issue in themiRNAworld concerns the assessment of
miRNA activity and function, both of which depend on themiRNA
targets and on the relative miRNA and target abundancy (Ebert
and Sharp, 2012; Leung and Sharp, 2010). The functional identi-
fication of miRNA targets is one of the most challenging tasks,
because a single miRNA often has hundreds of potential mRNA
targets. Conversely, several different miRNAs can combinatori-
ally impact the same mRNA target. It is obvious that the
ultimate biological effect of the miRNA will be determined by its
own concentration, but in addition by that of its multiple targets.
To make the situation even more complex, the biological effect
will be affected by the different disappearance rates of the multi-
ple targets. Finally, the arising evidence in mammals for the
existence of intracellular miRNA sponges such as ‘‘competing
endogenous RNA,’’ and more recently circular RNAs, probably
has to be integrated in the assessment of miRNA action (Hansen
et al., 2013). When considering the therapeutic potential of
miRNAs, it must be kept inmind that by aiming at several targets,
some displaying antagonizing effects, miRNAs could exert dual
actions. In the context of the miRNA-metabolism crosstalk, an
igniting question relates to the impact of circadian rhythms
(Kojima et al., 2011). This aspect is particularly relevant consid-
ering the fact that feeding (i.e., nutrients) modulates the circadian
clock and that the latter regulates metabolism.
A second fascinating issue relates to the observation that
certain mature miRNAs can re-enter the nucleus, where they
function in a noncanonical manner by directly regulating the
biogenesis of miRNAs including their own and the function of
long-noncoding RNA (Chen et al., 2012). This ‘‘nuclear’’ effect
of miRNA has to be taken into account in attempts to evaluate
the global biological repertoire of a particular miRNA.
A third issue to be examined concerns the significance of
extracellular miRNAs. An immediate benefit is their possible
use as disease biomarkers, but their biological functions remain
to be clarified. The enticing possibility that extracellular miRNAs,
and in particular the blood-borne ones, are indeed involved in
cell-cell communications would not only make inroads in basic
biology, but in addition would show promise for their use as
potential therapeutic tools.
Since their discovery, miRNAs have received enormous
attention, and their biological stature as natural actors in gene-
expression regulation is now clearly established. Although
important roadblocks exist, novel experimental tools are poised
to reveal their possible utility in the treatment of diseases eitheras therapeutic means themselves or as targets of therapeutic
interventions. Stringent collaborative endeavors are needed for
evaluating the miRNAs in the armamentarium of therapeutics
for human diseases.ACKNOWLEDGMENTS
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